Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protease-activated receptor-2 antagonists and agonists.

Robert M Scarborough1

  • 1Cardiovascular Chemistry, Millennium Pharmaceuticals, Inc., S. San Francisco, CA 94080, USA. bob.scarborough@mpi.com

Current Medicinal Chemistry. Cardiovascular and Hematological Agents
|August 20, 2004
PubMed
Summary

Developing specific antagonists for protease-activated receptors (PARs) is challenging. This review focuses on PAR-2, exploring its activators, roles in disease, and structure-activity relationships for PAR-2 modulators.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.

Bioorganic & medicinal chemistry letters·2009
Same author

Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR.

Bioorganic & medicinal chemistry letters·2009
Same author

Inhibitory effect of carboxylic acid group on hERG binding.

Bioorganic & medicinal chemistry letters·2006
Same author

Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor.

Bioorganic & medicinal chemistry letters·2004
Same author

Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration.

The Journal of biological chemistry·2004
Same author

Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors.

Bioorganic & medicinal chemistry letters·2004

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Protease-activated receptors (PARs) are G protein-coupled receptors activated by proteases.
  • Significant research has focused on PAR-1 antagonists, but PAR-2 remains less explored.
  • Challenges in PAR-2 research include identifying its activators and understanding its physiological roles.

Purpose of the Study:

  • To review the current knowledge on PAR-2 activating proteases.
  • To summarize the potential physiological and pathophysiological roles of PAR-2.
  • To discuss structure-activity relationships of PAR-2 agonists and antagonists.

Main Methods:

  • Literature review of existing research on PAR-2.
  • Analysis of studies identifying PAR-2 activating proteases.

Related Experiment Videos

  • Examination of structure-activity relationship data for PAR-2 modulators.

    • Main Results:

    • Limited understanding of PAR-2 activating proteases compared to other PARs.
    • Emerging evidence suggests PAR-2 involvement in various disease pathways.
    • Structure-activity relationship studies are beginning to yield insights into PAR-2 modulation.

    Conclusions:

    • Further research is needed to fully elucidate PAR-2 biology and its therapeutic potential.
    • Development of specific PAR-2 antagonists presents a significant challenge but holds therapeutic promise.
    • Comparative analysis with PAR-1 provides a framework for understanding PAR-2 modulator development.